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Abstract 
Restoring pluripotency using chemical compounds alone would be a major step forward in 
developing clinical grade pluripotent stem cells, but this has not yet been reported in human 
cells. We previously demonstrated that human amniocytes cultivated with valproic acid 
(VPA_AFS cells) acquired functional pluripotency whilst remaining distinct from embryonic 
stem cells (hESCs), questioning the relationship between modulation of cell fate and molecular 
regulation of the pluripotency network. Here, we used single cell analysis and functional assays 
to reveal that VPA treatment resulted in a homogenous population of self-renewing non-
transformed cells that fulfil hallmarks of pluripotency, i.e. a short G1 phase, a dependence on 
glycolytic metabolism, expression of epigenetic modifications on histones 3 and 4, and 
reactivation of endogenous OCT4 and downstream targets albeit at a lower level than that 
observed in hESCs. Mechanistic insights into the process of VPA-induced reprogramming 
revealed that it was dependent on OCT4 promoter activation, which was achieved 
independently of the P13K/AKT/mTOR pathway or GSK3 inhibition, but was concomitant 
with the presence of acetylated histones H3K9 and H3K56, which promote pluripotency. Our 
data identify for the first time the pluripotent transcriptional and molecular signature and 
metabolic status of human chemically-induced pluripotent stem cells.  
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Introduction 
 
The reprogramming of somatic cells to pluripotency was originally pioneered by forced 
expression of transcription factors (TFs) using retroviral transduction1. Alternative 
strategies have since been developed to minimise the number of TFs used2 and to 
produce footprint-free induced pluripotent stem cells (iPSCs) without genomic 
alterations3, 4. Ultimately, the complete replacement of ectopically expressed TFs by 
chemical compounds (CiPSCs) would hold much promise for the use of iPSCs 
derivates in regenerative medicine. To date, this has not yet been achieved in human 
cells. The two major barriers to chemical-based reprogramming are (1) to establish a 
cocktail of mutliple epigenetic modifiers and inhibitors that would reactivate the 
endogenous pluripotent network, and (2) to find a target cell source which chromatin 
configuration is most permissive to such chemical treatments.   
 
Paving the way for the generation of human CiPSCs, iPSCs have been generated 
from human fetal stem cells by ectopically expressing OCT4 alone5,6. This suggests 
that stem cells present during early fetal development may be more amenable to 
reprogramming than terminally differentiated cells found in adult tissues. However, the 
accessibility of the cells is of paramount importance for developing autologous 
CiPSCs. Similar to other fetal mesenchymal stem cells (MSCs)7, human amniocytes 
(amniotic fluid stem cells, i.e. AFS cells) are multipotent and differentiate readily into 
bone, fat and cartilage. They are not tumorigenic, present a low immunogenicity8, and 
maintain their phenotype and karyotype after cryopreservation and in vitro expansion, 
making them ideal candidates for translational use9. AFS cells are characterised by 
the expression of the standard MSC surface markers CD73, CD90 and CD10510,11, 
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along with SSEA4 and CD177. Whilst they are not pluripotent and do not express 
SOX2, NANOG, or OCT4A12-14,9 (the only isoform with a pivotal role in self-renewal 
and pluripotency15), they present a higher degree of plasticity compared to adult 
MSCs, are more rapidly and efficiently reprogramed to pluripotency16-18, and are 
amenable to reprogramming using only OCT46. 
We previously reported in two independent studies that human amniocytes cultivated 
on Matrigel in feeder-free hES cell conditions with the histone deacetylase inhibitor 
valproic acid (VPA, 2-propyl pentanoic acid)19, i.e. VPA_AFS cells, gained the capacity 
to form embryoid bodies (EBs) containing cells that expressed ectoderm (NESTIN, 
PAX6), primitive endoderm (BMP4), endoderm (CK3, CK19) and mesendoderm 
(GATA6) markers11-13. When injected subcutaneously into immunodeficient mice, 
VPA_AFS cells formed well-differentiated teratomas within 4-6 weeks, which 
contained derivatives of all three germ layers, as evidenced by immunostaining, i.e. 
ectoderm (-Tubulin, NESTIN, NR1), mesoderm (-ACTININ), and endoderm cells 
(SOX17, HNF-3, AFP) 11-13. After 6-8 weeks of in vitro expansion in ESC conditions, 
VPA_AFS cells (but not AFS cells) were capable of differentiating towards the 
definitive endoderm (CXCR4, SOX17+ and HNF-3+, immunostaining) when cultured 
in serum-free conditions in the presence of Activin-A. When cultured in hepatocyte 
permissive medium, VPA_AFS cells (but not AFS cells) also differentiated into 
ALBUMIN+ AFP+ cells which produced urea. These results show that compared to 
AFS cells, VPA_AFS cells have a higher developmental potential, and suggest that 
they have acquired functional pluripotency11-13. 
However, genome-wide transcriptome analysis of the entire VPA_AFS cell population 
revealed that, despite being clearly separated from AFS cells, they remain different 
from hES cells6-8. This questions the relationship between cell potency and molecular 
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state of the pluripotent network. To address this gap in knowledge, we used single cell 
analysis and a range of functional assays to comprehensively characterise VPA_AFS 
cells and understand how they relate to hES cells. We uncover for the first time that 
human amniocytes cultured in hESC conditions and treated with VPA aquired some 
molecular, epigenetic and phenotypic features of pluripotency, and that the effect of 
VPA is OCT4A-dependent. We observed a reactivation of endogenous OCT4 and 
downstream targets in all individual VPA_AFS cells (albeit levels were not as high as 
those found in hESCs), resulting in a short cell cycle G1 phase and a dependence on 
glycolytic metabolism. Together, these data indicate that human amniocytes are a 
candidate cell source for developing chemical-based protocols to revert human cells 
to the naïve pluripotent state, and to produce autologous clinical-grade pluripotent 
stem cells.  
 
 
RESULTS  
 
VPA_AFS cells aquired functional pluripotency but are molecularly different 
from hES cells 
 
The present study characterised the molecular state of the same three AFS cell 
samples which previously formed EBs and teratomas11-13. We first used the colony 
formation in soft agar assay to determine that VPA treatment did not induce the 
transformation of VPA_AFS cells, as evidenced by their inability to show anchorage-
independent growth (Supplementary Figure 1a). 
Flow cytometry showed that the pluripotency-associated cell surface markers TRA-1-
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60, TRA-1-81 and SSEA3, and the nuclear TFs NANOG and OCT4A were expressed 
in hES cells and absent in AFS cells but expressed in VPA_AFS cells, albeit plots 
showed overlapping tails with the isotype control for some of these proteins, which 
indicates the population is heterogeneous (Figure 1a). However, scatter plot analysis 
of the whole population transcriptome showed that VPA_AFS cells were molecularly 
distinct from hES cells (r = 0.84), with the heatmap of pluripotency-associated genes 
showing lower expression levels in VPA_AFS cells (Figure 1b).  
 
 
VPA_AFS cells gained OCT4 and NANOG expression with high efficiency 
 
As the results presented above were obtained on the whole population, it is possible 
that the low correlation (r = 0.84) between VPA_AFS cells and hES cells was due to 
the heterogeneity of the AFS cell population to reactivate endogenous OCT4 and 
NANOG. To measure the efficiency of the VPA treatment in AFS cells, we introduced 
OCT4-GFP (Cellomics Technology  PLV-10050-50) or NANOG-GFP vectors 
(Plasmid 21321: PL-SIN-Nanog-EGFP, Addgene) in order to detect OCT4 and 
NANOG expression. All three AFS cell samples transfected with NANOG-GFP and 
OCT4-GFP and cultured in D10 (DMEM + 10% FBS) were negative for cell surface 
marker TRA-1-60, which is considered one of the best markers for human pluripotent 
stem cells21, but gained TRA-1-60 expression upon VPA treatment (Figure 2). TRA-
1-60+ cells were then single cell sorted into four 96-well plates coated with Matrigel 
(total of 384 cells analysed for each condition) and placed in an incubator for an 
additional 28 days, during which GFP expression was monitored 7, 14 and 28 days 
later using an optical plate reader (Figure 2a). TRA-1-60 expression was maintained 
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homogeneously in almost all cells (>85% of the cell population) over 28 days. Optical 
analysis of the plates indicated that the cells formed clones of variable size all 
expressing GFP, indicating (1) that VPA treatment reactivated OCT4 and NANOG 
expression, (2) that the acquired phenotype (expression of TRA-1-60, OCT4 and 
NANOG) was stable, and (3) that VPA treatment was highly efficient (Figure 2b, 2c). 
We validated the use of OCT4-GFP lentiviral reporter approach by showing that GFP 
expression correlates with the pattern of OCT4 expression demonstrated by 
immunostaining (Figure 2d). 
 
VPA_AFS cells changed cell size, presented a short G1 phase and switched their 
metabolism towards glycolysis  
 
As previously demonstrated, VPA_AFS cells grew as compact colonies (Figure 3a), 
and a flow scatter analysis showed that the size of individual VPA_AFS cells was in 
average smaller that the size of the cells from the AFS cell population, i.e. forward 
scatter (FSC) median 278 vs. 809 (10000 cells analysed for each conditions) (Figure 
3b), although this observation alone does not indicate that the cells are pluripotent.  
 
Propidium iodine staining and flow cytometry analysis of the cell cycle showed that 
AFS cells predominantly presented a distribution typical of diploid DNA content in the 
G1 phase of the cell cycle, indicating that the cells were in a pre-replicative state. In 
contrast, VPA_AFS cells showed a shortened G1 phase and a longer S phase 
(synthesis of DNA) for each cycle, which resulted in a shorter G1/S-phase ratio, a 
feature associated with maintenance of the undifferentiated state in pluripotent stem 
cells22-24, with hES cells demosntrating a similar pattern (Figure 3c).  
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 To determine the metabolic phenotype of VPA_AFS cells, ATP levels were monitored 
dynamically by fluorescence (see Methods). The resistance to oligomycin treatment is 
indicative of a metabolic switch towards glycolysis. Mg provides an index of changing 
ATP concentration and is an indirect read-out for ATP depletion. The drop in ATP is 
thus proportional to the increase in fluorescence. The more prominent is the OXPHOS 
the greater will be the rise in fluorescence consequently plotted. The opposite occurs 
when OXPHOS is scares. Living AFS cells and VPA_AFS cells (1 million cells per 
sample, three samples tested for each group) positively loaded with the MgGreen dye 
were challenged with the chemical inhibitor of the Complex V oligomycin, and changes 
in fluorescence were recorded and quantified. In AFS cells, but not in VPA_AFS cells, 
we detected a clear and sustained increase in fluorescence within minutes (P<0.05), 
with the graph and chart plotting in corresponding to an increase in depletion (Figure 
3d). A greater contribution of mitochondria to energy metabolism and an oxidative 
phenotype could account for this increase in fluorescence intensity in AFS cells.  
We next examined mitochondrial oxidative metabolism using carbon dioxide (13CO2) 
production as a marker, as 13C-pyruvate is produced by glycolysis and then oxidized 
in the mitochondria to yield 13CO2. After 4 h incubation with [U-13C]-D-glucose, 13CO2 
released in the culture medium and in the sealed culture flasks air was measured. 
Compared to AFS cells (undifferentiated and differentiated down the osteoblast 
lineage), VPA_AFS cells demonstrated a significantly (P<0.05) lower production of 
13CO2 (P<0.05), which is indicative of a lower oxidative metabolism, albeit levels did 
not reach those of hES cells (Figure 3e).  
Together, these data indicated that VPA_AFS cells presented a higher dependance 
on glycolysis over OXPHOS, a feature associated with the pluripotent state in human 
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and mouse cells25, 26. 
 
Expression of markers associated with pluripotency in VPA_AFS cells 
 
We used immunofluorescence-based staining to detect the expression of 
pluripotency-associated proteins. We confirmed the flow cytometry results (Figure 1a) 
showing that endogenous OCT4 and NANOG proteins were expressed 
homogeneously in VPA_AFS cells (Figure 4a). Contrary to AFS cells, VPA_AFS cells 
also showed nuclear expression of DNA (cytosine-5-)-methyltransferase 3 beta 
(DNMT3B), ZFP42 (REX1), Oestrogen-related receptor beta (ESRRB) (which is 
known to interact with OCT4A to positively regulate NANOG expression27), LIN28A 
(an RNA-binding protein highly expressed in mammalian ESCs28), and NODAL (which 
signalling controls NANOG expression and functions to maintain pluripotency in 
human iPS cells29 in most cells) (Figure 4a). Interestingly, ESRRB was expressed in 
VPA_AFS cells, with some, but not all, cells also expressing NODAL, suggesting that 
VPA_AFS cells share features of both mouse ground and human primed state of 
pluripotency. In contrast to hES cells, but similar to epiblast stem (EpiS) cells, 
VPA_AFS cells had a high cloning efficiency and survived well when dissociated as 
single cells, which questions their developmental origin. As expected LIN28A was 
localized primarily to the cytoplasm in hES cells and absent in AFS cells whereas in 
VPA_AFS cells, we unexpectedly observed localization of LIN28A in the nucleus, 
outside the nucleoli. It has been reported that in hES cells, the RNA-binding protein 
musashi 1 (MSI1) enhances the localization of LIN28A to the nucleus outside the 
nucleoli to regulate miRNA biogenesis30, suggesting that VPA treatment may influence 
miRNA biogenesis. 
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VPA_AFS cells showed epigenetic modifications at histone 3 and 4 
 
Modification of lysines on the tails of histones H3 and H4 plays an important role in the 
regulation of chromatin organisation and transcription31, and histone acetylation 
contributes to the maintenance of a pluripotent state, thereby improving the 
accessibility of DNA to transcriptional machinery required for transcription initiation32. 
Here, we show that compared to AFS cells, VPA treatment induced acetylation at three 
histone H3 lysine residues, i.e. H3K9 (2.3; 2.4 and 2.3 time), K18 (1.3, 1.2 and1.3 
time) and K56 (1.7, 1.9 and 1.8 time) (Figure 4b). These histone modifications are 
associated with the pluripotent state, i.e. acetylated histone H3K56 controls 
transcriptional and translational processes by promoting pluripotency in ESCs33, whilst 
H3K18 acetylation is enriched at the promoters of OCT4, NANOG, SOX2 and KLF432, 
and H3K9 acetylation predict cell self-renewal34, 35 and reprogramming capacity36, 37.  
VPA_AFS cells also showed a slight 0.96 reduction in H4K16ac marks, which 
decrease promotes cellular longevity38, (Figure 4b). Finally, we observed a decrease 
(1.4; 1.2 and 1.2 time) in the trimethylation of lysine 20 of H4, H4K20(3Me) (Figure 
4b), which knockdown has been reported to increase the fraction of cells in S phase39-
40. 
 
 
The effects of VPA treatment depended on endogeneous OCT4A activation 
 
OCT4A, which was not expressed in AFS cells (Figure 4a), was expressed in 
VPA_AFS cells (Figure 1a and Figure 4a). To determine whether VPA directly 
activated OCT4A expression, we silenced endogenous OCT4 gene expression in AFS 
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cells and treated the cells with VPA (OCT4-shRNA VPA_AFS cells) (Figure 5a). We 
observed that VPA treatment failed to induce the expression of TRA-1-60, DNMT3B, 
LIN28A, NANOG, NODAL, NR6A1 and REX1, as visualised by immunofluorescence 
using the same exposure time (Figure 4a and Figure 5a), although ESRRB remained 
expressed (Figure 4a). To understand whether the absence of protein resulted from 
impeded translation or transcription, we assessed gene expression in (1) AFS cells, 
(2) VPA_AFS cells, (3) OCT4- shRNA VPA_AFS cells, (4) VPA_AFS cells following 
osteogenic differentiation and (5) hESCs (3 samples for each AFS-derived group) 
(Figure 5b). The results confirmed that silencing OCT4A inhibited VPA from inducing 
the transcriptional up-regulation of PODXL, ZFP42, DNMT3B, NR6A1, NANOG, 
LIN28A and BMI1. These data highlight OCT4A reactivation as the bottlneck of VPA-
induced modification of AFS cell identity towards an earlier state of cell fate potency.   
 
 
Single cell transcriptionanl profiling: homogenous expression of 14 
pluripotency-associated genes in VPA_AFS cells. 
 
We next investigated the heterogeneity of the VPA_AFS cell population using the 
Fluidigm microfluidics system platform41. This approach enabled us to simultaneously 
determine the expression level of 26 genes involved in pluripotency and of 10 lineage-
specific genes at the single-cell level in a total of 132 individual VPA_AFS cells from 
three different healthy donors and in hES cells (H1) (Figure 6a, Figure 7, Figure 8, 
Supplementary Figure 2, 3 and 4). The output of the runs is a 48x48 matrix of cycle 
threshold (Ct) values. All three samples showed similar gene expression patterns, as 
indicated by the similarity of the data among the three samples tested, indicating little 
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effect of the genotype. In all three samples, we determined that the VPA_AFS cell 
population was characterised by the homogeneous expression of OCT4, KLF4, SOX2, 
c-MYC, NANOG and LIN28A, TDGF1, NR6A1, DNMT3B, ZFP42, PODXL, SALL4, 
LEFTY1, and LEFTY2 (Figure 6a), which are not expressed in AFS cells (Figure 5b). 
The co-expression of TRA-1-60, DNMT3B and REX1 has been reported to distinguish 
human fully reprogrammed iPSCs from partially reprogrammed cells41. The 
reactivation of NR6A1 has been reported to distinguish pluripotent iPS cells from 
incompletely reprogrammed cells, and absence of expression of NR6A1 in iPSCs 
results in maintenance of residual pluripotency gene expression during differentiation 
and improper differentiation in vitro and in vivo42. These results, combined with data 
obtained on protein expression, identify a transcriptional state for VPA_AFS cells and 
confirm the homogeneity of the VPA_AFS cell population. We noted that KLF4, which 
is already expressed in AFS cells (expression level is about 1% of that of hES cells), 
reached the same level as hES cells. However, we observed that the levels of 
expression However, the other markers were lower in VPA_AFS cells than in hESCs 
cells (Figure 6a). To explore this, we next used quantitative RT-PCR to compare the 
levels of expression of the core circuitry of pluripotency (OCT4, SOX2 and NANOG) 
in VPA_AFS cells to hES cells, partially reprogrammed iPS cells (14 days of 
reprogramming) and bona fide reprogrammed iPS cells (21 days of reprogramming) 
derived from AFS cells (Figure 6b). We show that expression of OCT4, SOX2 and 
NANOG remained lower in bona fide iPS cells than in hES cells, and that  VPA_AFS 
cells are equivalent to iPS cells between 14 and 21 days of reprogramming (Figure 
6b).    
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Single cell transcriptionanl profiling: heterogenous expression of 12 
pluripotency-associated genes in VPA_AFS cells. 
 
Other pluripotency-associated genes showed bimodal expression in VPA_AFS cells, 
with a distinct sub-goup of cells expressing the gene (Ct value <30) and a second sub-
group showing weak or negligeable expression (Ct value >30). These markers 
included (1) the cyclin dependent kinase inhibition 1A and 2A CDKN1A and CDKN2A, 
(2) KLF5, (3) NODAL, (4) undifferentiated embryonic cell transcription factor 1 UTF1, 
(5) GDF3, (6) forkhead box protein 3 FOXD3, and (7) telomerase reverse transcriptase 
TERT (Figure 7). 
However, developmental pluripotency associated 2 and 5 (DPPA2 and DPPA5), 
Krüppel-like Factor 2 (KLF2) and fibroblast growth factor 4 (FGF4), were not 
expressed in VPA_AFS cells (Figure 7).    
As GDF3 and TDGF1 are expressed in hESCs that are found at the top of the 
pluripotency gene expression hierarchy43, we quantified the percentage of VPA_AFS 
cells co-expressing both genes. We found that 67% VPA_AFS cells co-expressed 
GDF3 and UTF1 (defined by a Ct value <35), with a subset of 30% cells showing 
higher levels of expression (Ct value < 25) for both genes (Figure 7). To explore this, 
we next investigated the molecular profile of the sub-population of cells expressing the 
naïve pluripotency profile, i.e. GDF3+ UTF1+ (GU+) cells, and compared it to the GDF-
UTF- (GU-) cells for the 24 genes studied. Results showed that GU+ cells were not 
the cells expressing the heterogeneous cluster of pluripotency associated markers. 
However, GU+ cells expressed NODAL at a higher level (26.21.1 vs. 31.51.3, 
meanstd, P<0.01;) albeit still showing heterogeneity of the population 
(Supplementary Figure 3a). Performing the same transcriptome analysis on 
  
14 
FOXD3+ cells revealed that FOXD3+ cells do not differ from FOXD3- cells for GDF3, 
NODAL, TERT, KLF2, but interestingly FOXD3+ cells showed higher levels of 
transcripts for the pluripotency markers FGF4 (36.60.8 vs. 38.20.3, P<0.01), UTF1 
(27.61.1 vs. 33.11.1, P<0.01), CDKN1A (25.61.2 vs. 29.81.2, P<0.05), CDKN2A 
(34.30.8 vs. 37.60.4, P<0.01), KLF5 (29.90.9 vs. 34.50.7, P<0.01), DPPA5 
(33.50.5 vs. 36.00.4, P<0.01), and DPPA2 (32.30.5 vs. 34.90.4, P<0.01) 
(Supplementary Figure 3b), indicating that FOXD3+ cells, which represent 47% of 
the whole VPA_AFS cell population correspond to the highest expressing cells of the 
heterogeneous cluster of pluripotency associated transcripts.  
 
 
Principle component analysis reveals the hierarchical organisation of VPA_AFS 
cells  
 
Principle component analysis of the data41 for the  pluripotency-associated genes 
studied (Figure 8) revealed a group of 8 core pluripotency genes (OCT4, KLF4, 
DNMT3B, SALL4, ZFP42, NR6A1, PODXL and SOX2) whose expression accounted 
for 68% of the observed variance between VPA_AFSC cells and AFS cells. A second 
group of 18 genes (LEFTY1, LEFTY2, NODAL, NANOG, TDGF1, GDF3, UTF1, TERT, 
DPPA2, DPPA5, CDKN1A, CDKN2A, KLF2, KLF5, FOXD3, LIN28A, c-MYC and 
KLF5) explained 41% of the variance within the population.  
VPA_AFS cells showed low level of expression for HLA-A, HLA-B, and HLA-C, and 
for markers of specific lineages (NESTIN, MAP2, T, MSX1, SOX17, GATA4 and 
PAX6), and expression levels were not higher that those found in hES cells, confirming 
that VPA_AFS cells were in a pluripotent state (Supplementary Figure 4).  
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VPA-mediated OCT4 promoter activation occured independently of GSK3 or 
P13K/AKT/mTOR signaling 
 
VPA has previously show to enhance OCT4 promoter activity through activation of the 
P13K/AKT/mTOR signalling pathway activated nuclear receptors in mouse myogenic 
cells57-58. Therefore, to gain mechanistic insight into the process of VPA 
reprogramming, we examined whether the same mechanisms was operating in VPA-
AFS cells. However, treatment of AFS cells with 1mM VPA for 2 or 24 hours did not 
affect the levels of phospho-AKT or phospho-mTOR (Supplementary Figure 5a), 
indicating that activation of the P13K/AKT/mTOR signalling pathway is not required 
for VPA to mediate OCT4 activation and revert human AFS cells to pluripotency.  
VPA has pleiotropic effects which involve various pathways and multiple molecular 
targets such as glycogen synthase kinase 3 (GSK3) 58. Here, we show that VPA 
treatment induced GSK3 inhibition in AFS cells, which could be recapitulated by 
treating AFS cells with the GSK3 inhibitor CHIR99021 (Supplementary Figure 5b). 
However, treatment of AFS cells with CHIR99021 alone failed to revert the cells to 
pluripotency, indicating that the primary target of VPA in AFS cells is not GSK3 
(Supplementary Figure 5c). 
 
DISCUSSION 
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Here, we established a correlation between the molecular regulation of the pluripotent 
state in human amniocytes cultured in hESC conditions supplemented with VPA, and 
a description based on chromatin modifications, metabolism, cell cyle and gene 
expression to understand the molecular quality behind the behaviour of pluripotency.  
AFS cells, which multipotent differentiation ability is routinely maintained in standard 
MSC cultured conditions, were adapted to feeder-free hESC culture conditions before 
being treated with the histone deacetylase inhibitor VPA for 5-10 days, after which 
VPA_AFS cells were subsequently expanded for up to 30 days in feeder-free hESC 
conditions. Short-term treatment with VPA reactivated the expression of endogenous 
OCT4A (along with its downstream targets), and maintained its expression level for as 
long as the cells were cultured in conditions maintaining the undifferentiated state of 
pluripotent cells. Contrary to AFS cells, VPA_AFS cells expressed TRA-1-60 and 
maintained its expression long-term. In addition to OCT4A and TRA-1-60, single cell 
analysis and immunostaining revealed that VPA_AFS cells homogeneously 
expressed other pluripotency-associated genes, including DNMT3B, REX1, NANOG, 
ESSRB, LIN28A, KLF4, CMYC, SOX2, NR6A1, TDGF1 and SALL4, albeit the levels 
of expression found in VPA_AFS cells were lower than those observed for hESCs, 
explaining the results obtained on whole population transcriptome analysis, which 
established only a R=0.84 correlation between VPA_AFS cells and hESCs.  
These results indicate that the chromatin conformation of AFS cells is permissive to 
chemically-induced regulation of gene expression, and that the level of OCT4A 
expression reached in VPA_AFS cells was sufficient to confer the ability of the cells to 
form well-differentiated teratomas in vivo, and to differentiate into endoderm and 
ectoderm-derived lineages in vitro.  
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Although VPA_AFS cells fulfilled several functional, molecular, epigenetic and 
metabolic characteristics that have recently been described in De Los Angeles et al.44 
as criteria of pluripotency, it is important to note that VPA_AFS cells were close, but 
different form hESCs. For example, only a subset of VPA_AFS cells expressed the 
pluripotency-associated genes NODAL, TERT, UTF1 and GDF3, with only 30% of the 
cells co-expressing UTF1 and GDF3. Interestingly, cells expressing FOXD3 showed 
higher transcript levels for other markers, such as CDKN1A, CDKN2A, FGF4, UTF1, 
KLF5, DPPA5 and DPPA2, suggesting they have reached a more advanced stage 
reprogramming, and it would be interesting to investigate the stability of these cells 
over longer period of culture. In mouse embryonic fibroblasts, an alternative class of 
pluripotent cells independent of standard definitions of iPS state, referred as fuzzy 
cells, were recently characterised, indicating that pluripotent cells can exist as different 
and unique states that are alternative to hESCs45-48 The molecular events underlying 
functional pluripotency are not completely understood, and data from mouse and 
human studies indicate that pluripotency can be regained functionally without the cells 
reverting their cellular identity to hESCs.  
We also demonstrated here that OCT4A was indispensible for VPA to modify the 
cellular identity of AFS cells. Although OCT4 has previously been identified as the 
bottleneck for cellular reprogramming49, the chemical replacement of OCT4 has yet 
only been achieved in mouse embryonic fibroblasts (MEFs) with a cocktail of seven 
small-molecule compounds50, 51, or with the use of BrdU (bromodeoxyuridine)52. Our 
data indicate that AFS cells can be used as a model of human cells to study the 
chemical modulation of the pluripotency network via activation of endogenous OCT4A, 
allowing to correlate cell functionality with molecular profiling.  
The mechanisms by which VPA reactivated endogenous OCT4A expression in AFS 
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cells remain speculative. VPA has pleiotropic effects on cell function, either promoting 
differentiation in vitro, facilitating the process of cellular reprogramming to 
pluripotency2, 19, 53, suppressing reprogramming-induced senescence in human iPS 
cells54, inhibiting autophagy via modulation of the mTORC1 signaling pathway55, and 
promoting cell cycle progression and glycolysis56. Interestingly, VPA also enhances 
OCT4 promoter activity through the activation of the P13K/Akt/mTOR signaling 
pathway in mouse myogenic cells57, 58. It has also been established that mTOR 
complex 1 (mTORC1) signaling regulates histone H3K acetylation on lysine-5659-61 to 
promote nucleosome disassembly at promoter regions of Oct434. We found that in AFS 
cells, VPA did not activate OCT4 promoter through the P13K/Akt/mTOR signaling 
pathway or GSK3 inhibition. However, the increase in acetylation of H3K9 and H3K56 
marks observed in VPA_AFS cells suggest that activation of endogenous OCT4A 
might have been mediated by histone H3K56 acetylation. Elucidating the mechanisms 
by which VPA promoted endogenous OCT4 activity in human AFS cells provides a 
platform to study other small compounds which could act synergistically with VPA, 
paving the way for the development of chemical reprogramming of human adult 
somatic cells62.  
 
 
METHODS 
 
Cell culture. Human amniocytes, i.e. amniotic fluid stem (AFS) cells, were isolated 
after informed consent from the amniotic fluid at 12 weeks of gestation (normal 
pregnancy), which was obtained under ultrasound guidance and according to the 
ethical approval given by the Research Ethics Committees of Hammersmith & Queen 
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Charlotte’s Hospitals (08/H0714/87) in compliance with national guidelines 
(Polkinghorne) for the collection of fetal tissue for research. The AFS cells from three 
individuals with normal karyotype  (sample 1, 2 and 3) were selected for c-KIT 
expression and expanded (104 cells/cm2) on plastic culture dishes without feeders in 
Dulbecco’s modified Eagle’s medium (DMEM-HG) (Invitrogen) supplemented with 
10% fetal bovine serum (Biosera), 2 mmol/l L-glutamine, 50 IU/ml penicillin and 50 
mg/ml streptomycin (Gibco- 2 incubator. The cells were 
subsequently transferred onto Matrigel-coated plates (Becton Dickinson) in NutriStem 
XF/FF (Stemgent) for 2-5 days, after which valproic acid (VPA, 1 mM; Sigma-Aldrich) 
or CHIR99021 (10 M, Stemgent) was added to the medium for a period of 5 days, 
after which the cells were subsequently cultured in NutriStem alone without VPA 
(VPA_AFS cells)13. NutriStem medium was replaced every 24 h. Human ES cell line 
H1 (WiCell Research Institute), was cultured in feeder-free conditions on Matrigel-
coated plates in mTeSR (Stem Cell Technologies). NTERA2 cells (ATCC) were 
cultured in DMEM supplemented with 10% FBS). Microdissection passaging 
techniques were combined with type IV collagenase (1 mg/ml, Invitrogen) or dispase 
(1.5 mg/ml, Invitrogen) treatment to split cells at a ratio of 1:3. For comparative analysis 
to partially reprogrammed and bone fide iPS cells, AFS cells were reprogrammed 
using an episomal mixture (Invitrogen kit A15960) over 25 days.  
 
Colony formation in soft agar. Anchorage-independent growth was determined by 
suspending VPA_AFS cells and NTERA2 cells (5 x 103 cells ) in DMEM containing 
10% FBS and 0.3% of low melting agarose (Gibco BRL). The cells were plated in 12-
well plates over a layer of solidified DMEM containing 10% FBS and 0.6% agarose. 
The medium was replaced every 3 days. Colonies were photographed after 3 weeks.  
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Transfection Transduction with OCT4-GFP and NANOG-GFP. We used OCT4-
GFP lentivirus and NANOG-GFP lentivirus (Cellomics Inc) in which the GFP reporter 
gene is expressed from the OCT4 and NANOG promoter that is active when cells are 
in an undifferentiated state. If the OCT4 or NANOG promoter is gradually inactivated, 
the GFP reporter is down-regulated. For transduction with the lentivirus, AFS cells 
were plated in six-well plates with 2 ml D10 culture medium and then placed back in 
the CO2 incubator for 18 h prior to transduction. Aliquots of lentiviral stock were mixed 
with transduction medium (10 ug/ml polybrene in 2 ml growth medium). The cells were 
removed from the incubator, and the culture medium was aspirated and replaced with 
transduction medium containing the virus. The cultures were centrifuged at 1200 x g 
for 60 min at room temperature to increase infection efficiency. The plates were 
incubated at 37°C for 10 h in the CO2 incubator. The virus-containing transduction 
medium was then discarded and replaced it with fresh growth medium. The cells were 
left to incubate for 24–48 h to enable the accumulation of the expressed protein in the 
target cells, after which the cells were selected using puromycin.  
 
OCT4 gene silencing. OCT4 was silenced in AFS cells using OCT4-short hairpin 
(sh)RNA (h) lentiviral particles (sc-36123, Insight Biotechnologies), which are provided 
as transduction-ready viral particles for gene silencing, following the manufacturer’s 
instructions. After transduction, AFS cells expressing the OCT4-shRNA were selected 
using puromycin.   
 
Flow cytometry and confocal immunostaining. The antibodies used for flow 
cytometry and immuno-staining are listed in Supplementary Table 1. The OCT4 
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antibody (sc-5279, Santa Cruz) is a mouse monoclonal IgG raised against amino acids 
1-134 of OCT4 of human origin, and does not cross–react with OCT4 isoform B. For 
flow cytometry, the cells were detached and dissociated into single cells using dispase 
(Sigma-Aldrich), and resuspended in FACS buffer (PBS, 1% Bovine Serum Albumin; 
5 x 105 cells/100 ul FACS-buffer). For cell-surface staining, the AFS cells and 
VPA_AFS cells were replated as single cells in chamber slides to assess 
heterogeneity of expression and cellular localisation of antigens. The VPA-AFS OCT4-
shRNA cells were directly stained on cover slips placed in the cell culture dishes. The 
cells were  
cells were washed once in FACS buffer, fixed for 10 min in 0.01% PFA, washed twice 
with PBS, resuspended in permeabilisation buffer (PBS, 1% Triton) and stained as 
above. All samples were analysed via FACScalibur flow cytometry (Becton Dickinson) 
and analysed using CellQuest software. Negative controls were IgG or IgM primary 
antibody-specific isotypes. 
For confocal immuno-staining, the cells were fixed and stained as previously 
described7. Fluorescence confocal laser scanning microscopy images were collected 
on a Leica TCS SP5 (X1000 PL APO oil objective) and transferred to Adobe 
Photoshop (Adobe Systems). Secondary antibodies were donkey anti-mouse and 
anti-rabbit IgG (Jackson ImmunoResearch Laboratories). hESC cells (H1) served as 
positive controls. 
 
Quantitative RT-PCR. Total RNA was extracted using the RNeasy Mini RNA kit 
(Qiagen) and cDNA was synthesised using Pd(N)6 random hexamers (Amersham 
Pharmacia Biotech) and 1 ml of 200U M-MLV Reverse Transcriptase in the presence 
of dNTPs (Promega), according to the manufacturer’s instructions. The generated 
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cDNA was amplified using the ABI StepOne Sequence Detector system (Applied 
Biosystems) and TaqMan Assay probes, as listed in Supplementary Table 2 (Thermo 
Fisher Scientific). Samples were normalised against the internal control (18S).  
 
Single-cell quantitative RT-PCR. VPA_AFS cells were dissociated into single cells 
using dispase, resuspended in FACS buffer supplemented with 2% FBS (Biosera) and 
sorted into 96-well 0.2 ml PCR plates containing 5 μl of 2x CellsDirect Reaction Mix 
(Invitrogen) and 0.1 μl SUPERase-in (Ambion). Reverse transcription and specific 
transcript amplification were performed using SuperScript III Reverse Transcriptase / 
Platinum Taq Mix (Invitrogen) on the thermocycler as previously described45. The 
amplified cDNA was then loaded into Biomark 48.48 Dynamic Array chips using the 
Nanoflex IFC Controler (Fluidigm). We then used a microfluidic platform to conduct 
single cell qPCR in nanolitre reaction volumes using the Biomark machine. Threshold 
cycle (Ct), as a measurement of relative fluorescence intensity, was extracted by the 
Fluidigm Real-Time PCR Analysis software. The endogenous control gene was 18S. 
 
Carbon dioxide production: CO2 production was used as a marker of mitochondrial 
oxidative metabolism. The cells were cultured in 6-well plates at a density of 104 
cells/cm2. The culture media was then exchanged with media equivalent 
supplemented with [U-13C] D-glucose, and each well was covered with a glass 
microfibre filter disc (Whatman GF/A), soaked in 3.5 M NaOH and incubated for four 
hours. Following this, 500 μl culture medium was transferred to a 12-ml glass tube 
(Exetainer, Labco, UK), and glacial acetic acid (100 μl) was injected through the 
septum to release 13CO2 from bicarbonate. The filter paper was also removed and 
placed in a 12-ml glass tube, and CO2 was released by the addition of glacial acetic 
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acid. 13CO2/12CO2 was measured in the gas phase via isotope ratio mass 
spectrometry. The ratio of 13CO2 to 12CO2 in bicarbonate is proportional to the quantity 
of oxidised glucose48. 
 
Fluorescent evaluation of ATP dynamics: One day prior to the experiment, AFS 
and VPA_AFS cells were seeded on 22 mm round borosilicate cover glasses and 
incubated at 37°C, 5% CO2, to reach a confluence of approximatively 40% at imaging. 
The adherence of VPA_AFS cells to the glass surface was facilitated by coating the 
cover glasses with Matrigel. Cellular ATP levels were indirectly measured with the cell 
permeant green fluorescent Mg2+ indicator Magnesium Green™, which emission 
intensity increases without a shift in wavelength after binding to Mg2+. Briefly, the cells 
were loaded with 5 μM Magnesium Green™ for 30 min at 37°C and 5% CO2. After 
loading, the cover glasses were washed three times with recording medium, and 
mounted within an Attofluor metal cell chamber for microscopy (Molecular ProbesTM, 
Thermo Fisher Scientific, A-7816). Continuous live imaging was carried out using a 
Zeiss LSM 510 confocal laser scanning microscope (inverted configuration on an 
Axiovert 200 frame) equipped with a thermostated chamber (37°C) and a Fluar 
40x/1.30 oil-immersion objective. A field of view with at least 10 cells was selected 
prior to time-series imaging of the Magnesium Green™ fluorescent signal. An argon-
ion laser was used to excite the dye, and a HTF 488/543 dichroic mirror with a BP 
500/550 band-pass filter was used to capture the emitted fluorescence. The settings 
were held constant between experiments and were chosen to reduce photobleaching 
of the fluorophore (laser power: 1%). The pinhole was set to produce an optical slice 
of ~2 μm. After the administration of oligomycin (2.5 μg/ml) to block (1) the proton flux 
through the F1F0-ATPase and (2) cytosolic ATP depletion, images were acquired every 
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second to follow the time-course of cytosolic ATP depletion. Regions of interest were 
demarcated by selecting the entire cell surface area, and the average intensity of the 
florescent signal was measured. Raw data were averaged in Prism 6, and the slopes 
of the generated curves were calculated in Microsoft Excel 10 through linear 
regression. Greater Mg2+ availability induces a faster rate of increase in Magnesium 
Green fluorescence intensity; thus the slope of the graph represents an indirect 
method to evaluate ATP depletion. 
 
Western blotting: Protein lysates were generated using standard lysis buffer (50 mM 
Tris 7.5pH, 150 mM NaCl, 1 mM EDTA) containing 1% SDS with sonication to disrupt 
genomic DNA. Twenty-five ug β-mercaptoethanol denatured lysates were separated 
on a 12.5% -PAGE gel and blotted onto a Protran nitrocellulose transfer membrane 
(Whatman, Life Sciences). The membrane was blocked in 5% milk PBS-T (phosphate-
buffered saline with 0.1% Tween-20) and immunoprobed with antibodies raised 
against different peptides containing different histone modifications (H3K9ac Abcam 
Cell Signalling 96715; H3K18ac Abcam 1191, H3K56ac epitomics 2134-1, H4K20me3 
Millipore 07-463, H3 Abcam 10158 and H4 Abcam 1971 loading controls). The 
secondary antibodies used were goat anti-rabbit conjugated to horseradish 
peroxidase (HRP) (Dako) and rabbit anti-mouse-HRP (1:5000) (Dako). The 
experiments were performed in triplicate. Bands were quantitated via direct scanning 
of the western blot films with a HP Scanjet 4890 and quantified using ImageJ software. 
For analysis of the P13K/AKT/mTOR signalling pathway, the antibodies for 
phosphorylated AKT (pAKT), phosphorylated mTOR (pmTOR) and total mTOR 
antibodies were purchased from from Cell Signaling (40585, 55365, 29725) and 
the antibody for total AKT was purchased from Abcam (ab8932). 
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Statistical analysis: Statistical analysis was performed using InStat Version 3.0a 
statistical software (GraphPad Software, La Jolla, CA ). P < 0.05 was significant. 
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FIGURE LEGENDS 
Figure 1 | VPA_AFS cells are similar yet different from hES cells. (a) Flow 
cytometry for expression of the cell surface markers TRA-1-60, TRA-1-81, SSEA3, 
and for the nuclear markers NANOG and OCT4 in hES cells, AFS cells (whole 
population) and VPA_AFS cells (whole population). The red tracing shows the isotype 
control and the blue tracing shows the primary antibody. (b) Scatter plot (log2) of 
VPA_AFS cells (whole population) and two hESCs lines (H1 and H9), and heatmap of 
pluripotency associated genes generated via similarity measure Pearson correlation 
(color scaling per row/gene) using the transcriptome profiling data of the cells acquired 
previously using the Human Ref-8 v3.0 expression BeadChip platform (NCBI Gene 
expression omnibus, GSE26940).  
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Figure 2 | Efficiency of the VPA treatment. (a) AFS cells transfected with OCT4-
GFP or NANOG-GFP reporters genes were cultured on plastic culture dishes in growth 
medium composed of DMEM supplemented with 10% FBS before being transferred 
on Matrigel-coated dishes in Nutristem medium for 7 to 14 days prior to exposure to 1 
mM VPA for 5 days (VPA_AFS Cells). TRA-1-60+ cells were subsequently single-cell 
sorted into four 96-well plates, and cultured for another 28 days in Nutristem 
(supplemented with a ROCK inhibitor to increase cloning efficiency) on Matrigel. In 
parallel, the whole VPA_AFS cell population was also maintained in culture for 28 
days. (b) The number of OCT4-GFP+ or NANOG-GFP+ clones was monitored at 7, 14 
and 28 days in the 96-well plates, and the GFP intensity was recorded at 7 and 28 
days using an optical plate reader. (c) TRA-1-60 expression was assessed by flow 
cytometry (the red tracing shows the isotype control and the blue tracing shows the 
primary antibody) in the VPA_AFS cell population after 28 days in culture in Nutristem. 
(d) NANOG-GFP and OCT4-GFP immunostaining in hES cells. OCT4-GFP was 
validated using immunosfluorescence in hES cells using OCT4A-specific antibody. 
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Figure 3 | Cell size, cell cycle and metabolism of AFS and VPA_AFS cells. (a) 
Phase contrast images of VPA_AFS cells (left panel, x40 magnification) and confocal 
immuno-fluorescence showing the morphology of the cells growing as compact 
colonies (right panel). Nuclei stained with DAPI (blue). Actin filaments stained with 
Alexa Fluor 594 Phalloidin (red). Scale bar 50μm. (b) Flow scatter and histogram 
showing differences in the relative size of parental AFS cells (pink) and VPA_AFS cells 
(blue). (c) Flow cytometry of AFS cells, VPA_AFS cells expanded for 28 days in 
NutriStem on Matrigel, and hES cells showing DNA stained with propidium iodide. G1 
indicates cells with 2n cellular DNA content, S indicates cells undergoing mitosis, and 
G2/M indicates cells with 4n cellular DNA content. (d) Magnesium green fluorescence 
intensity staining, as a function of ATP levels, over time for parental AFS cells and 
VPA_AFS cells following the addition of 2.5 μg/ml OLIGO. Representative traces 
depicting oligomycin-induced ATP depletion for parental AFS cells and VPA_AFS 
cells. Cells were loaded with Mg2+ indicator Magnesium GreenTM and AM to obtain an 
indirect measurement of cellular ATP levels over time. Upon the addition of oligomycin 
(2.5 μg/ml), a rapid increase in Magnesium GreenTM emitted fluorescence is 
observable in AFS cells. The bar chart on the right reports the average slopes of 
increase in Magnesium GreenTM fluorescence for AFS cells and VPA_AFS cells (n = 
3, p < 0.005). (e) Oxidative phosphorylation studied using carbon isotope labelling of 
[U-13C] glucose, followed by CO2 release, isotype analysis and quantification in AFS 
cells, VPA_AFS cells, hES cells, and AFS cells differentiated for 2 weeks down the 
osteogenic lineage. *** P<0.001. 
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Figure 4 | VPA_AFS cells gain the expression of pluripotency markers and 
undergo histone modifications. (a) Confocal immuno-fluorescence showing 
expression of DNMT3B, REX1, OCT4A, NANOG, ESRRB, LIN28A, and NODAL 
stained with FITC (green) in hESCs, AFS cells, VPA_AFS cells and OCT4-shRNA 
cells using the same exposure time. The nuclei are stained with DAPI (blue). Actin 
filaments are stained with Alexa Fluor 594 Phalloidin (red). Scale bar 50μm. (b) 
Western blotting for histone modification detection in AFS cells and VPA_AFS cells. 
Lysates were made and western blot was performed with antibodies against 
acetylated and methylated lysines located on the N-terminal histone tails and 
compared with the total H3 and H4 loading controls. 
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Figure 5 | Blocking OCT4A expression in AFS cells prevents VPA from inducing 
the up-regulation of pluripotency markers. (a) Flow cytometry showing OCT4 and 
TRA-1-60 expression in OCT4-shRNA VPA_AFS cells. The red tracing shows the 
isotype control and the blue tracing shows the primary antibody. (b) Quantitative RT-
PCR for the housekeeping genes 18S and ACTIN,  and for the pluripotency markers 
OCT4A, PODXL, ZFP42, DNMT3B, NR6A1, TGFB1, NANOG, LIN28A, and BMI-1 in 
AFS cells (n = 3, blue bars), VPA_AFS cells (n = 3, red bars), OCT4-shRNA VPA_AFS 
cells (n = 3, yellow bars), AFS cells differentiated down the osteogenic lineage (n = 3, 
green bars), and hESCs (n=2, black bars)., error bars are s.e.m. 
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Figure 6 | Single-cell transcriptional profiling: homogenous expression of 14 
pluripotency-associated genes in VPA_AFS cells. (a) Population distribution for 3 
different VPA_AFS cell samples (S1, S2 and S3, 46 cells per sample) and hESCs 
showing homogeneity in the expression of 14 genes associated with pluripotency 
(OCT4, KLF4, SOX2, CMYC, NANOG, LIN28A, TDGF1, NR6A1, DNMT3B, REX1, 
PODXL, SALL4, LEFTY2 and LEFTY1). Each point represents the expression value 
of a single cell. The horizontal axis represents the Ct value. The red bar indicates the 
mean Ct value. (b) Quantitative real-time RT-PCR for OCT4, SOX2 and NANOG in 
hES cells (n = 3, blue bars), iPS cells at day 14 (n = 3, red bars), day 21 (n = 3, yellow 
bars), fully reprogrammed iPS cells (n = 3, green bars) and VPA_AFS cells (n = 3, 
black bars). Housekeeping genes for normalisation were GAPDH and 18S. error bars 
are s.e.m 
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Figure 7 | Single-cell transcriptional profiling: heterogenous expression of 12 
pluripotency-associated genes in VPA_AFS cells. (a) Population distribution for 3 
different VPA_AFS cell samples (S1, S2 and S3, 46 cells per sample) and hESCs 
showing heterogeneity in the expression of 12 genes associated with pluripotency 
(CDKN1A, CDKN2A, KLF5, NODAL, UTF1, GDF3, FOXD3, TERT, KLF2, DPPA2, 
DPPA5, and FGF4). The red bar indicates the mean Ct value. (c) Distribution of Ct 
values for UTF1 (horizontal axis) and GDF3 (vertical axis) in VPA_AFS cells.  
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Figure 8 | Principal component analysis of VPA_AFS cells. Principal component 
analysis for 26 pluripotency genes in 3 samples (138 cells analysed per gene) and 
corresponding biplots. 
 
 
 
